Neutralising antibody responses against SARS-CoV-2 Omicron BA.4/5 and wild-type virus in patients with inflammatory bowel disease following three doses of COVID-19 vaccine (VIP): a prospective, multicentre, cohort study

作者：Zhigang Liu, James L. Alexander, Kaixing Le, Xin Zhou, Hajir Ibraheim, Sulak Anandabaskaran, Aamir Saifuddin, Kathy Weitung Lin, Leon R. McFarlane, Laura Constable, Rocío Seoane, Nikhil Anand, Claire Bewshea, Rachel Nice, Andrea D’Mello, Gareth Jones, Sharmili Balarajah, Francesca Fiorentino, Shaji Sebastian, Peter M. Irving, Lucy Hicks, Horace R. Williams, Alexandra Kent, Rachel Linger, Miles Parkes, Klaartje Kok, Kamal Patel, Julian Teare, Daniel M. Altmann, Rosemary J. Boyton, Ailsa Hart, Charlie W. Lees, James Goodhand, Nicholas A. Kennedy, Katrina M. Pollock, Tariq Ahmad, Nick Powell, Ijeoma Chukwurah, Sulaimaan Haq, Jonathan W. Lo, Parita Shah, Stephanie Wilken-Smith, Anitha Ramanathan, Mikin Patel, Lidia Romanczuk, Rebecca King, Jason Domingo, Djamila Shamtally, Vivien Mendoza, Joanne Sanchez, Hannah Stark, Bridget Knight, Louise Bee, Charmaine Estember, Anna Barnes, Darcy Watkins, Sam Stone, John M. Kirkwood, Marian Parkinson, Helen Gardner‐Thorpe, Kate Covil, Lauranne Derikx, Beatriz Gros Alcalde, Irish Lee, Bessie Cipriano, Giuseppe Ruocco, Manisha Baden, Graham Cooke, Evgenia Kourampa, Ciro Pasquale, Elena Robisco-Diaz, Suhaylah Bhatti · 发表于：EClinicalMedicine · 年份：2023 · DOI：10.1016/j.eclinm.2023.102249 · 被引用次数：8 · 研究领域：SARS-CoV-2 and COVID-19 Research、Animal Virus Infections Studies、vaccines and immunoinformatics approaches

Background: Patients with inflammatory bowel disease (IBD) receiving anti-TNF and JAK-inhibitor therapy have attenuated responses to COVID-19 vaccination. We aimed to determine how IBD treatments affect neutralising antibody responses against the Omicron BA.4/5 variant. Methods: In this multicentre cohort study, we prospectively recruited 340 adults (69 healthy controls and 271 IBD) at nine UK hospitals between May 28, 2021 and March 29, 2022. The IBD study population was established (>12 weeks therapy) on either thiopurine (n = 63), infliximab (n = 45), thiopurine and infliximab combination therapy (n = 48), ustekinumab (n = 45), vedolizumab (n = 46) or tofacitinib (n = 24). Patients were excluded if they were being treated with any other immunosuppressive therapies. Participants had two doses of either ChAdOx1 nCoV-19 or BNT162b2 vaccines, followed by a third dose of either BNT162b2 or mRNA1273. Pseudo-neutralisation assays against SARS-CoV-2 wild-type and BA.4/5 were performed. The half maximal inhibitory concentration (NT50) of participant sera was calculated. The primary outcome was anti-SARS-CoV-2 neutralising response against wild-type virus and Omicron BA.4/5 variant after the second and third doses of anti-SARS-CoV-2 vaccine, stratified by immunosuppressive therapy, adjusting for prior infection, vaccine type, age, and interval between vaccination and blood collection. This study is registered with ISRCTN (No. 13495664). Findings: Both heterologous (first two doses a...